DOI : 10.1055/s-00000059

Pneumologie

Issue S 01 · Volume 73 · March 2019 DOI: 10.1055/s-009-42542


60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.
München, 13.–16.03.2019

Kongresspräsident: Prof. Dr. med. Jürgen Behr, München
Abstracts (HTML) List of Authors
P41
Plate, T; Höpfert, S; Beier, J: Efficacy and tolerability of LABA/LAMA fixed-dose combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the treatment of COPD in daily practice – results of the non-interventional DETECT study
P144
Kostikas, K; Mackay, A; Vogelmeier, C; Frent, SM; Pfister, P; Gupta, P; Banerji, D; Patalano, F; Wedzicha, J: Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in the FLAME Study
P148
Greulich, T; Vogelmeier, C; Mackay, A; Lossi, N; Aalamian-Mattheis, M; Nunez, X; Pagano, V; Patalano, F; Clemens, A; Kostikas, K: Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial
P178
Scuri, M; Singh, D; Fabbri, LM; Guasconi, A; Vezzoli, S; Prunier, H; Muraro, A; Petruzzelli, S; Papi, A: Risk of pneumonia and exacerbations with single inhaler extrafine triple therapy compared to indacaterol/glycopyrronium: Post-hoc Analysis of the TRIBUTE Study
P256
Forster, A; Abenhardt, B; Pabst, S; Hänsel, M; Marseille, A; Kondla, A; Buhl, R: Körperliche Funktionsfähigkeit, Allgemeinbefinden und Zufriedenheit mit Tiotropium/Olodaterol im Behandlungsalltag von COPD-Patienten in Deutschland
P314
Scuri, M; Singh, D; Fabbri, LM; Valente, I; Guasconi, A; Vezzoli, S; Prunier, H; Cohuet, G; Muraro, A; Petruzzelli, S; Papi, A: Single Inhaler Extrafine Triple Therapy improves Quality of Life in COPD Patients compared to Indacaterol/Glycopyrronium: Post-hoc Analysis of the TRIBUTE study
P467
Lipson, DA; Barnhart, F; Boucot, I; Crim, C; Brealey, N; Criner, G; Dransfield, M; Halpin, DMG; Kilbride, S; Han, MK; Lange, P; Lomas, DA; Martinez, FJ; Singh, D; Naya, I; Jones, CE; Wise, R: Comparison of LAMA/LABA vs. ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial
P468
Criée, CP; Kardos, P; Worth, H; Lossi, N; Kostikas, K; Vogelmeier, C; Buhl, R: Duale Bronchodilatation vs. Dreifachtherapie bei COPD: Ein direkter Vergleich in der DACCORD Beobachtungsstudie
P469
Vogel-Claussen, J; Schönfeld, C; Kaireit, TF; Voskrebenzev, A; Czerner, CP; Renne, J; Tillmann, HC; Berschneider, K; Hiltl, S; Bauersachs, J; Welte, T; Hohlfeld, J: Indacaterol/Glycopyrronium verbessert pulmonale Perfusion und Ventilation bei überblähten COPD Patienten
P477
Müllinger, B; Schick, J; Burgess, G; Snape, S: Verbesserung der Lungendeposition bei der Inhalation von Glucocorticoiden
P484
Lipson, DA; Barnhart, F; Boucot, I; Crim, C; Brealey, N; Criner, G; Dransfield, M; Halpin, DMG; Kilbride, S; Han, MK; Lange, P; Lomas, DA; Martinez, FJ; Singh, D; Naya, I; Jones, CE; Wise, R: Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial
P491
Dransfield, M; Crim, C; Criner, G; Halpin, DMG; Han, MK; Jones, CE; Kilbride, S; Lange, P; Lipson, DA; Lomas, DA; Martinez, FJ; Singh, D; Wise, R: Risk of Exacerbation and Pneumonia with Single Inhaler Triple versus Dual Therapie in IMPACT
P535
Hänsel, M; Bambach, T; Wachtel, H: Reduced environmental impact of a reusable soft mist inhaler
P544
Hövelmann, R; Georges, G; Bahari Javan, S; Melchior, K; Beck, E; Criée, CP; Geßner, C: TriOptimize I: Real World Evidence with extrafine single inhaler Triple Therapy in COPD
P561
Wachtel, H; Hänsel, M; Eicher, J: Reusable soft mist inhaler: maintaining aerosol performance